Are Epithelial Ovarian Cancers of the Mesenchymal Subtype Actually Intraperitoneal Metastases to the Ovary?
desmoplasia
mesenchymal
metastases
molecular subtype
ovarian cancer
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2020
2020
Historique:
received:
02
04
2020
accepted:
29
06
2020
entrez:
9
8
2020
pubmed:
9
8
2020
medline:
9
8
2020
Statut:
epublish
Résumé
Primary ovarian high-grade serous carcinoma (HGSC) has been classified into 4 molecular subtypes: Immunoreactive, Proliferative, Differentiated, and Mesenchymal (Mes), of which the Mes subtype (Mes-HGSC) is associated with the worst clinical outcomes. We propose that Mes-HGSC comprise clusters of cancer and associated stromal cells that detached from tumors in the upper abdomen/omentum and disseminated in the peritoneal cavity, including to the ovary. Using comparative analyses of multiple transcriptomic data sets, we provide the following evidence that the phenotype of Mes-HGSC matches the phenotype of tumors in the upper abdomen/omentum: (1) irrespective of the primary ovarian HGSC molecular subtype, matched upper abdominal/omental metastases were typically of the Mes subtype, (2) the Mes subtype was present at the ovarian site only in patients with concurrent upper abdominal/omental metastases and not in those with HGSC confined to the ovary, and (3) ovarian Mes-HGSC had an expression profile characteristic of stromal cells in the upper abdominal/omental metastases. We suggest that ovarian Mes-HGSC signifies advanced intraperitoneal tumor dissemination to the ovary rather than a subtype of primary ovarian HGSC. This is consistent with the presence of upper abdominal/omental disease, suboptimal debulking, and worst survival previously reported in patients with ovarian Mes-HGSC compared to other molecular subtypes.
Identifiants
pubmed: 32766252
doi: 10.3389/fcell.2020.00647
pmc: PMC7380132
doi:
Types de publication
Journal Article
Langues
eng
Pagination
647Subventions
Organisme : BLRD VA
ID : I01 BX004974
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA208753
Pays : United States
Informations de copyright
Copyright © 2020 Hu, Taylor-Harding, Raz, Haro, Recouvreux, Taylan, Lester, Millstein, Walts, Karlan and Orsulic.
Références
Nat Rev Clin Oncol. 2015 Apr;12(4):239-45
pubmed: 25707631
Biochim Biophys Acta. 2013 Oct;1831(10):1533-41
pubmed: 23500888
Cancer Res. 2013 Aug 15;73(16):5016-28
pubmed: 23824740
Gynecol Oncol. 2017 Dec;147(3):503-508
pubmed: 28964622
Radiology. 2015 Mar;274(3):742-51
pubmed: 25383459
Cancer Cell. 2012 Nov 13;22(5):571-84
pubmed: 23153532
Cancer Discov. 2016 Dec;6(12):1342-1351
pubmed: 27856443
J Clin Oncol. 2017 Feb 20;35(6):613-621
pubmed: 28029317
Clin Cancer Res. 2008 Aug 15;14(16):5198-208
pubmed: 18698038
J Natl Cancer Inst. 2014 Apr 03;106(5):
pubmed: 24700803
EMBO Mol Med. 2013 Jul;5(7):1051-66
pubmed: 23666744
Gynecol Oncol. 2018 Aug;150(2):227-232
pubmed: 29925470
Gynecol Oncol. 2019 Feb;152(2):368-374
pubmed: 30448260
Cancer Lett. 2016 Nov 28;382(2):203-214
pubmed: 27609069
Nat Rev Clin Oncol. 2010 Nov;7(11):623-31
pubmed: 20981128
Nat Med. 2015 Nov;21(11):1350-6
pubmed: 26457759
JCO Clin Cancer Inform. 2019 Apr;3:1-9
pubmed: 31002564
Cancer Res. 2008 May 15;68(10):3645-54
pubmed: 18483246
Oncotarget. 2016 Jan 26;7(4):4167-82
pubmed: 26716409
Am J Pathol. 2003 Feb;162(2):391-402
pubmed: 12547698
Sci Rep. 2016 May 17;6:26001
pubmed: 27184229
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
PLoS Med. 2015 Feb 24;12(2):e1001789
pubmed: 25710373
J Gynecol Oncol. 2017 Jul;28(4):e40
pubmed: 28541632
Gynecol Oncol. 2016 Sep;142(3):458-64
pubmed: 27444035
Nat Commun. 2015 Dec 04;6:8971
pubmed: 26634437
Nat Med. 2011 Oct 30;17(11):1498-503
pubmed: 22037646
Gynecol Oncol. 2015 Dec;139(3):394-400
pubmed: 26348314
Nat Rev Dis Primers. 2016 Aug 25;2:16061
pubmed: 27558151
Nat Genet. 2015 Apr;47(4):320-9
pubmed: 25706628
J Pathol. 2019 Mar;247(3):305-319
pubmed: 30374975
Cancer Res. 2010 Jul 15;70(14):5770-7
pubmed: 20570891
Sci Rep. 2015 Nov 04;5:16066
pubmed: 26530441
Clin Cancer Res. 2018 Oct 15;24(20):5037-5047
pubmed: 30084834
Gynecol Oncol. 2019 Feb;152(2):221-222
pubmed: 30704616
Clin Cancer Res. 2014 Jun 15;20(12):3280-8
pubmed: 24756370
Br J Surg. 2018 Jan;105(2):e204-e211
pubmed: 29341165
J Exp Med. 2019 Mar 4;216(3):688-703
pubmed: 30710055
BMC Cancer. 2015 Feb 26;15:85
pubmed: 25881093
Clin Cancer Res. 2017 Aug 1;23(15):4077-4085
pubmed: 28280090
PLoS One. 2014 Apr 14;9(4):e94476
pubmed: 24732363
J Natl Cancer Inst. 2017 Aug 1;109(8):
pubmed: 28376187
Clin Cancer Res. 2014 Feb 1;20(3):711-23
pubmed: 24218511
Cell. 2004 Jun 25;117(7):927-39
pubmed: 15210113
Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21677-82
pubmed: 21098274
Clin Cancer Res. 2016 Aug 15;22(16):4095-104
pubmed: 27151745
Nat Genet. 2016 Jul;48(7):758-67
pubmed: 27182968
J Natl Cancer Inst. 2014 Sep 30;106(10):
pubmed: 25269487
Nature. 2019 May;569(7758):723-728
pubmed: 31043742
J Clin Invest. 2013 Jan;123(1):517-25
pubmed: 23257362
Gynecol Oncol. 2019 Feb;152(2):223-227
pubmed: 30503050
Nat Genet. 2008 May;40(5):650-5
pubmed: 18408720